Shire Share Discussion Threads

[philanderer] 11/1/2018 10:01

11th jan Deutsche buy tp 5000p

reiterates

[steeplejack] 10/1/2018 10:20

From Alphaville yesterday:Here's HSBC.We had previously noted that we believed Shire had alreadygiven up on its 2020 guidance but also noted that given the anticipated competition in haemophilia, Shire may need to consider writing down the carrying value of some of the Baxalta acquisition. Now that it has officially reduced its 2020 guidance, investors should rationally question whether a partial Baxalta write-down may be next.. Not a surprise, but the reduction will do Shire's credibility no favours. Although the reduction in 2020 revenue guidance should not come as a major surprise, the fact that it has occurred at all (especially in light of some vocal opposition at the time to doing the USD32bn Baxalta deal), will do Shire's credibility no favours, in our view. Shire now has two pivotal events in 2018: the Haven-4 data with competitor drug Hemlibra (mid-year) and a decision on its corporate structure (H2)

[philanderer] 10/1/2018 09:15

10th jan JP Morgan overweight tp 5000p

reiterates

[philanderer] 10/1/2018 00:28

Market report:

Pharma giant Shire clawed back 44p to £37.09. It plunged 5.4pc yesterday after revising its 2020 sales target and plans to spin off its ADHD unit. The consensus of City analysts kept Shire on their “buy” lists but HSBC’s Steve McGarry argued that the company might have to soon also consider a write-down of its Baxalta division, which was acquired in 2016.

[ygor705] 09/1/2018 22:39

Even if a suitor fails to emerge a simple demerger would work for me. To date, I've never lost a penny from a demerger situation and I see no reason why this should not be the case here.

[ruethewhirl] 09/1/2018 22:38

The discussion on Alphaville is worth a read.

Some takeaways: Share price fall overdone, earnings estimates were puffed up after the Baxalta acquisition were overly optimistic and unlikely to be met.

IMHO, I think Donald Trump might end up being our best friends on this one.

The tax law reforms in the US will surely help clear the way for an approach, hopefully in the not too distant future, although the structural shifts underway at Shire might cause potential suitors to hold off with a view to making a move on one of the devolved pieces.

Patience will be rewarded here, I'm sure of it.

[philanderer] 09/1/2018 17:35

Hopefully the takeover rumours will start again ;-)

just noticed from earlier today fwiw...


Shire Pharmaceuticals: Citigroup reiterates buy with a target price of 5,500p

[mbmiah] 09/1/2018 16:55

Could it the old DCB.....I think probably

[zho] 09/1/2018 11:45

HSBC and JPM views being discussed at

[philanderer] 08/1/2018 23:49

Full interview with Shire CEO Flemming Ørnskov

video:

[philanderer] 08/1/2018 23:46

CEO Flemming Ornskov presenting at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018.. video:

[philanderer] 08/1/2018 23:27

Bought back a few today before the close. Hopefully as rue says the fall has been overdone.

Luck to all.


Analysts at HSBC said in November that Shire should reconsider its 2020 guidance after Roche reported positive clinical data from its hemophilia agent Hemlibra, a potential blockbuster which threatens some of Shire's products.

Shire had already been dealt a blow in June when U.S. regulators approved a generic competitor to Lialda, its drug to treat ulcerative colitis.

Ornskov, however, said the setbacks had to be weighed against "significantly accelerated growth" in its immunology franchise. "The prospects for Shire mid-to long term have not changed," he added.

[ruethewhirl] 08/1/2018 23:00

Think the sell off just reflects short term money exiting on the loss of possibility making of a quick buck on breakup.

Wouldn't be surprised if some of that drop was regained over the next few sessions when the dust settles.

The revised forecasts (which were originally made two years ago after the Baxalta acquisition) were in line with analyst estimates according to the Telegraph.

The overall tone of the update was actually pretty bullish.

[cflather2000] 08/1/2018 19:25

Just when we were getting back there. Will this pick back up a few % tomorrow or continue to fall?

[montyhedge] 08/1/2018 19:21

Market did not like this news, can't see the point.

[swedeee] 08/1/2018 17:01

eurgh what a pain. long old road this

[brain smiley] 08/1/2018 15:47

$17-18 billion instead of the previous target of $20.Profit downgrades likely.

[romeike] 08/1/2018 15:10

That does seem likely. For now they are splitting the businesses into separate divisions with distinct reporting. It therefore seems more likely than not that the businesses are being prepared for separate listings. This is good news for investors and both of the separate companies will be highly attractive for takeover, though punters hoping for an immediate split will be disappointed about waiting until H2 2018.

[billytkid2] 08/1/2018 14:48

Split confirmed.

[romeike] 05/1/2018 23:00

Will be glad when the review is out of the way regardless of the decision. The uncertainty is holding back a recovery in the share price.

[scobak] 05/1/2018 20:56

must be love.

[ruethewhirl] 05/1/2018 18:03

Well sounds like Feb 14 then.

[redtom1] 05/1/2018 10:32

I asked Shire the same question and this was their response


Dear Mr XXXXX, I apologize if you think that our communication about the timing of sharing the update was not clear. We have been very consistent in our messaging to clarify that by year end could be literally by year end (which is now passed), by early Jan or at full year results and this is still our official message.

Clear as mud and not very professional to say the least.

[justiceforthemany] 04/1/2018 18:30

What happened to the end of year update? CEO talking rubbish again and can't meet targets or deadlines. Still tipped (again) for M&A in 2018.

[mbmiah] 29/12/2017 09:29

What a mess this is becoming